Next round of COVID-19 shots in fall will target latest omicron strain
The next round of COVID-19 vaccines will target one of the latest versions of the coronavirus
Your support helps us to tell the story
As your White House correspondent, I ask the tough questions and seek the answers that matter.
Your support enables me to be in the room, pressing for transparency and accountability. Without your contributions, we wouldn't have the resources to challenge those in power.
Your donation makes it possible for us to keep doing this important work, keeping you informed every step of the way to the November election
Andrew Feinberg
White House Correspondent
The next round of COVID-19 vaccines will target one of the latest versions of the coronavirus, the Food and Drug Administration said Friday.
FDA's decision came one day after an agency panel of outside advisers supported the recipe change. The agency told vaccine makers to provide protection against just one omicron strain, known as XBB.1.5.
Today's shots include the original coronavirus and an earlier version of omicron. They do still help prevent severe disease and death even as XBB variants have taken over. But protection gradually wanes over time and was short-lived against milder infection even before the virus, inevitably, evolved again.
The three U.S. companies that make COVID-19 shots said this week they had geared up to make the formula change, in anticipation of making many millions of doses available for the fall. One company, Pfizer, said it could have at least some doses ready as early as next month.
The Centers for Disease Control and Prevention will eventually decide whether to recommend the shot for nearly all Americans or just for certain high-risk groups.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.